In addition to this product adoption by CBMG, CryoStor and HypoThermosol, BioLife's companion cell storage and shipping media, have been used in at least 250 regenerative medicine applications, including several late-stage clinical trials.
BioLife's customer base has grown to over 2,000 companies, universities and clinical centers in the regenerative medicine, drug discovery and biobanking markets.
According to the Foundation for the National Institutes of Health, there are 27m Americans with osteoarthritis, and symptomatic Knee Osteoarthritis occurs in 13% of persons aged 60 and older.
The International Journal of Rheumatic Diseases, 2011 reports that approximately 57m people in Chinasuffer from KOA. Currently no treatment exists that can effectively preserve knee joint cartilage or slow the progression of KOA.
Current common drug-based methods of management, including anti-inflammatory medications (NSAIDs), only relieve symptoms and carry the risk of side effects.
Patients with KOA suffer from compromised mobility, leading to sedentary lifestyles; doubling the risk of cardiovascular diseases, diabetes, and obesity; and increasing the risk of all causes of mortality, colon cancer, high blood pressure, osteoporosis, lipid disorders, depression and anxiety.
According to the Epidemiology of Rheumatic Disease (Silman AJ, Hochberg MC. Oxford Univ. Press, 1993:257), 53% of patients with KOA will eventually become disabled.
Cellular Biomedicine develops proprietary cell therapies for the treatment of cancer and degenerative diseases.
The company conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory.
CBMG has GMP facilities in China, consisting of twelve independent cell production lines, all designed and managed according to both China and US GMP standards.
The company recently commenced two Phase I human clinical trials in China using CAR-T to treat relapsed/refractory CD19+ B-cell Acute Lymphoblastic Leukemia and Refractory Diffuse Large B-cell Lymphoma (DLBCL) as well as an ongoing Phase I trial in China for AlloJoin (CBMG's "Off-the-Shelf" Allogeneic Human Adipose-derived Mesenchymal Stem Cell) for the treatment of Knee Osteoarthritis.
BioLife Solutions develops, manufactures and markets biopreservation media products and smart shipping containers connected to a cloud-hosted cold chain management app to improve the quality of delivery logistics for cells, tissues, and organs.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes